Prolaris Predicts Absolute Benefit in Risk of Metastasis of ADT added to RT in Prostate Cancer Patients

Dr. Jonathan David Tward presented findings at last month's American Society of Clinical Oncology's 2023 meeting that demonstrated Prolaris's ability to accurately predict the absolute risk reduction (ARR) in metastasis risk with the addition of ADT to RT versus RT alone across all NCCN risk group categories.

While ADT is effective at slowing the progression of prostate cancer by suppressing androgen production, it is often associated with serious side effects such as cardiovascular events, diminished quality of life, and increased risk of dementia. When considering the use of androgen deprivation therapy (ADT), patients and providers need to weigh the benefits of its use, such as reduction in risk of developing metastasis versus the risk of the respective side-effects.

In Tward's findings presented at ASCO 2023, the authors sought to personalize the absolute reduction in risk of metastasis of ADT added to RT in patients with prostate cancer using Prolaris.

Prolaris delivers a personalized risk assessment of a patient's prostate cancer by combining the independent cell-cycle progression (CCP) score with CAPRA (UCSF Cancer of the Prostate Risk Assessment) to produce a cell-cycle risk (CCR) score, which best predicts the aggressiveness of prostate cancer. By cross-analyzing Prolaris's multi-modal threshold (MMT), below which the benefits of adding ADT wane compared to the adverse side effects, and previously published data from The Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP), this study looked at a cohort of patients treated with RT alone and the relative benefit of ADT added to RT.

The results showed an average 0.86% absolute risk reduction of adding ADT to RT in patients with CCR scores below the MMT and 8.2% for patients above the MMT. Furthermore, patients with CCR scores at the MMT had a predicted absolute risk reduction of 3.7%. These results establish Prolaris's ability to predict the absolute risk reduction of metastasis when ADT is added to RT, regardless of NCCN risk group.

Join Myriad on July 31 at 7PM EST for the webinar unveiling of the NEW Prolaris report. Save the date and register today: https://myriad.zoom.us/webinar/register/WN_gAHnAgbXSTGLTN_A4z_CKQ#/registration.

-30-